Braf V600 Mutation clinical trials

Explore recruiting braf v600 mutation clinical trials.

Recruiting braf v600 mutation studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Braf V600 Mutation trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Clinical Activity of RO7276389 Alone and in Combination with Cobimetinib in Participants with BRAF-V600 Mutation-Positive Advanced Solid Tumor or BRAF-V600 Mutation-Positive Melanoma with Central Nervous System Metastases

Spain, Poland, Belgium, Denmark

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

PET-DOPA Metabolic Detection and Characterization of Untreated Brain Metastases of Bronchial, Breast and Melanoma Cancer (DOPACER)

France

Therapeutic exploratory (Phase II) EU CTIS Study details

EORTC 1612-MG: Combination of targeted therapy (encorafenib and binimetinib) followed by combination of immunotherapy (ipilimumab and nivolumab) vs immediate combination of immunotherapy in patients with unresectable or metastatic melanoma with BRAF V600 mutation: an EORTC randomized phase II study (EBIN)

Netherlands, Italy, France, Germany, Spain, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

BEPCOME-MB: Phase 2, randomised trial testing the addition of upfront stereotactic radiosurgery to binimetinib, encorafenib plus pembrolizumab in comparison with binimetinib, encorafenib plus pembrolizumab alone in patients with BRAFV600 mutationpositive melanoma with brain metastasis

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Surgical or radiotherapeutic intervention concerning large singular stable to progressive metastases in patients with BRAFV600-mutated melanoma receiving treatment with Encorafenib + Binimetinib

Germany

Therapeutic use (Phase IV) EU CTIS Study details

Braf V600 Mutation trials by city

Braf V600 Mutation in Toronto Braf V600 Mutation in Vancouver Braf V600 Mutation in Montreal Braf V600 Mutation in Calgary Braf V600 Mutation in Edmonton Braf V600 Mutation in Ottawa Braf V600 Mutation in Winnipeg Braf V600 Mutation in Quebec City Braf V600 Mutation in Hamilton Braf V600 Mutation in Kitchener Braf V600 Mutation in London Braf V600 Mutation in Halifax Braf V600 Mutation in New York Braf V600 Mutation in Los Angeles Braf V600 Mutation in Chicago Braf V600 Mutation in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease